European Journal of Clinical Pharmacy

Volume 22 - Issue 3, July-September 2020

SHORT REPORTS

HIDRADENITIS SUPPURATIVA AND ANAKINRA

LLAMAS MOLINA JOSÉ MARÍA, AYEN RODRÍGUEZ ÁNGELA, CANCELA DÍAZ BÁRB ARA, GALVEZ MORENO MARINA, RUIZ VILL AVERDE RICARDO

Anakinra is a recombinant IL-1 receptor inhibitor commonly used for the treatment of autoinflammatory diseases in rheumatology. Successful off-label use of anakinra has been reported in different cases of severe HS. Several reports, in addition to our case, show that patients’ selection remains important since not all patients with HS respond well to anti-IL1 therapy, and further clinical investigation is needed to help on the predictive response to the different biological treatments.

ANAKINRA – ANTI-IL1 – BIOLOGICAL DRUG – HIDRADENITIS SUPPURATIVE – SYSTEMIC THERAPY

Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25€